XML 56 R45.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Business Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Schedule of Revenue, Operating Income and Total Assets by Reportable Segment | The following tables present segment results for the years ended December 31, 2024, 2023 and 2022 (in millions):
|  | Year Ended December 31, 2024 |
|  | BSI BioSpin |  |  | BSI CALID |  |  | BSI NANO |  |  | BEST |  |  | Total |
Segment revenue from external customers |  | $ | 905.7 |  |  | $ | 1,093.5 |  |  | $ | 1,098.3 |  |  | $ | 268.9 |  |  | $ | 3,366.4 |
Intersegment revenue |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 14.1 |  |  |  | 14.1 |
Total segment revenue |  | $ | 905.7 |  |  | $ | 1,093.5 |  |  | $ | 1,098.3 |  |  | $ | 283.0 |  |  | $ | 3,380.5 |
Segment expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  | $ | 437.7 |  |  | $ | 465.4 |  |  | $ | 518.9 |  |  | $ | 222.5 |  |  | $ | 1,644.5 |
Selling, general and administrative |  |  | 158.9 |  |  |  | 270.2 |  |  |  | 290.8 |  |  |  | 21.5 |  |  |  | 741.4 |
Research and development |  |  | 92.5 |  |  |  | 111.7 |  |  |  | 164.7 |  |  |  | 3.9 |  |  |  | 372.8 |
Segment Operating income |  | $ | 216.6 |  |  | $ | 246.2 |  |  | $ | 123.9 |  |  | $ | 35.1 |  |  | $ | 621.8 |
Reconciliation of Total operating income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate, elimination and other (a) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 103.8 |
Unallocated expenses (b) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 264.9 |
Total consolidated operating income |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 253.1 |
Interest and other income (expense), net |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (46.2 | )
Income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 206.9 |
|  | Year Ended December 31, 2023 |
|  | BSI BioSpin |  |  | BSI CALID |  |  | BSI NANO |  |  | BEST |  |  | Total |
Revenue |  | $ | 798.5 |  |  | $ | 960.4 |  |  | $ | 941.9 |  |  | $ | 263.7 |  |  | $ | 2,964.5 |
Intersegment revenue |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 17.0 |  |  |  | 17.0 |
Total segment revenue |  | $ | 798.5 |  |  | $ | 960.4 |  |  | $ | 941.9 |  |  | $ | 280.7 |  |  | $ | 2,981.5 |
Segment expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  | $ | 374.8 |  |  | $ | 393.2 |  |  | $ | 438.2 |  |  | $ | 225.9 |  |  | $ | 1,432.1 |
Selling, general and administrative |  |  | 134.7 |  |  |  | 238.7 |  |  |  | 228.0 |  |  |  | 19.3 |  |  |  | 620.7 |
Research and development |  |  | 77.8 |  |  |  | 96.4 |  |  |  | 117.3 |  |  |  | 3.0 |  |  |  | 294.5 |
Segment Operating income |  | $ | 211.2 |  |  | $ | 232.1 |  |  | $ | 158.4 |  |  | $ | 32.5 |  |  | $ | 634.2 |
Reconciliation of Total operating income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate, elimination and other (a) |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 87.9 |
Unallocated expenses (b) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 109.4 |
Total consolidated operating income |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 436.9 |
Interest and other income (expense), net |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 107.3 |
Income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 544.2 |
|  | Year Ended December 31, 2022 |
|  | BSI BioSpin |  |  | BSI CALID |  |  | BSI NANO |  |  | BEST |  |  | Total |
Revenue |  | $ | 696.7 |  |  | $ | 822.2 |  |  | $ | 787.0 |  |  | $ | 224.8 |  |  | $ | 2,530.7 |
Intersegment revenue |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 12.3 |  |  |  | 12.3 |
Total segment revenue |  | $ | 696.7 |  |  | $ | 822.2 |  |  | $ | 787.0 |  |  | $ | 237.1 |  |  | $ | 2,543.0 |
Segment expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  | $ | 320.6 |  |  | $ | 330.8 |  |  | $ | 373.2 |  |  | $ | 186.2 |  |  | $ | 1,210.8 |
Selling, general and administrative |  |  | 121.0 |  |  |  | 200.0 |  |  |  | 185.2 |  |  |  | 18.0 |  |  |  | 524.2 |
Research and development |  |  | 67.4 |  |  |  | 75.0 |  |  |  | 90.5 |  |  |  | 2.5 |  |  |  | 235.4 |
Segment Operating income |  | $ | 187.7 |  |  | $ | 216.4 |  |  | $ | 138.1 |  |  | $ | 30.4 |  |  | $ | 572.6 |
Reconciliation of Total operating income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate, elimination and other (a) |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 67.0 |
Unallocated costs (b) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 72.9 |
Total consolidated operating income |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 432.7 |
Interest and other income (expense), net |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (18.8 | )
Income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 413.9 |
a) Represents c orporate costs and intersegment eliminations not allocated to the reportable segments. Unallocated costs include general and administrative expenses not directly incurred by the segments such as professional fees incurred for the quarterly reviews and annual audit of the consolidated financial statements, personnel costs of corporate accounting, finance, legal and IT resources, and other expense items. b) Unallocated expenses consist of costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets, costs associated with our global information technology transition initiatives, and other costs Total assets by segment are as follows for the years ended December 31, (in millions):
|  | 2024 |  |  | 2023 |
BSI BioSpin, BSI CALID, BSI NANO & Corporate |  | $ | 5,648.4 |  |  | $ | 4,110.6 |
BEST |  |  | 199.8 |  |  |  | 186.0 |
Eliminations and other (a) |  |  | (41.5 | ) |  |  | (46.7 | )
Total assets |  | $ | 5,806.7 |  |  | $ | 4,249.9 |
a) Assets not allocated to the reportable segments and eliminations of intercompany transactions.
Schedule of revenue and property, plant and equipment, net by geographical area | Long-lived assets (which include property, plant and equipment, net and operating lease right of use assets) by geographical area are as follows for the years ended December 31, (in millions):
|  | 2024 |  |  | 2023 |  |  | 2022 |
Germany |  | $ | 370.0 |  |  | $ | 350.2 |  |  | $ | 309.6 |
United States |  |  | 188.0 |  |  |  | 124.9 |  |  |  | 58.8 |
Switzerland |  |  | 134.1 |  |  |  | 127.0 |  |  |  | 98.5 |
Rest of Europe |  |  | 91.8 |  |  |  | 57.4 |  |  |  | 42.5 |
Asia Pacific |  |  | 22.2 |  |  |  | 22.1 |  |  |  | 22.1 |
Other |  |  | 8.7 |  |  |  | 9.8 |  |  |  | 6.7 |
Total long-lived assets |  | $ | 814.8 |  |  | $ | 691.4 |  |  | $ | 538.2 |
Summary of capital expenditures and depreciation and amortization by segment | Total capital expenditures and depreciation and amortization by segment are presented below for the years ended December 31, (in millions):
|  | 2024 |  |  | 2023 |  |  | 2022 |
Capital Expenditures: |  |  |  |  |  |  |  |  |
BSI BioSpin |  | $ | 22.8 |  |  | $ | 23.9 |  |  | $ | 14.5 |
BSI CALID |  |  | 34.1 |  |  |  | 31.4 |  |  |  | 33.9 |
BSI NANO |  |  | 19.3 |  |  |  | 13.9 |  |  |  | 20.2 |
Corporate |  |  | 14.8 |  |  |  | 10.2 |  |  |  | 9.1 |
BEST |  |  | 24.3 |  |  |  | 27.5 |  |  |  | 51.5 |
Total capital expenditures |  | $ | 115.3 |  |  | $ | 106.9 |  |  | $ | 129.2 |
Depreciation and Amortization: |  |  |  |  |  |  |  |  |
BSI BioSpin |  | $ | 41.0 |  |  | $ | 25.7 |  |  | $ | 22.6 |
BSI CALID |  |  | 67.0 |  |  |  | 29.3 |  |  |  | 20.7 |
BSI NANO |  |  | 61.7 |  |  |  | 48.0 |  |  |  | 35.6 |
Corporate |  |  | 5.7 |  |  |  | 4.7 |  |  |  | 3.9 |
BEST |  |  | 8.4 |  |  |  | 7.2 |  |  |  | 6.0 |
Total depreciation and amortization |  | $ | 183.8 |  |  | $ | 114.9 |  |  | $ | 88.8 |

X
- Definition Tabular disclosure of the total capital expenditures and depreciation and amortization by segment for each reportable segment. + References No definition available. + Details
Name: | brkr_ScheduleOfCapitalExpendituresAndDepreciationAndAmortizationBySegmentTableTextBlock
Namespace Prefix: | brkr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration